Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review

High-mobility group box 1 (HMGB1) is a versatile protein with nuclear and extracellular functions. In the extracellular milieu, HMGB1 binds to several receptors, notably the receptor for advanced glycation end-products (RAGE). The expressions of HMGB1 and RAGE have been described in a variety of can...

Full description

Saved in:
Bibliographic Details
Published in:Contemporary oncology (Poznań, Poland) Poland), 2016-01, Vol.20 (6), p.425-429
Main Author: paper, Review
Format: Article
Language:English
Subjects:
hematological malignancies
HMGB1
leukemia
lymphoma
RAGE
Review Paper
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c481t-fd388cad59552442c668e953438b702d37cce086abe59a1a23622ec97c90705a3
cites
container_end_page 429
container_issue 6
container_start_page 425
container_title Contemporary oncology (Poznań, Poland)
container_volume 20
creator paper, Review
description High-mobility group box 1 (HMGB1) is a versatile protein with nuclear and extracellular functions. In the extracellular milieu, HMGB1 binds to several receptors, notably the receptor for advanced glycation end-products (RAGE). The expressions of HMGB1 and RAGE have been described in a variety of cancers. However, the clinical values of HMGB1 and RAGE in haematological malignancies have yet to be evaluated. A systematic search through PubMed and the Web of Science for articles discussing the role of HMGB1 and RAGE in haematological malignancies produced 15 articles. Overexpression of HMGB1 was reported to be associated with malignancy and, in certain studies, poor prognosis and tumour aggressiveness. Only one included study investigated the clinical value of RAGE, in which no significant difference was found between expression of RAGE in CLL neoplastic cells and nonmalignant controls. The discussed associations of HMGB1 and RAGE with clinicopathological characteristics of patients with haematological malignancies warrants further investigation into the prognostic and diagnostic value of both of these molecules.
doi_str_mv 10.5114/wo.2016.65600
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_13ab2152b5bb470295648367351f43d1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_13ab2152b5bb470295648367351f43d1</doaj_id><sourcerecordid>4313266441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-fd388cad59552442c668e953438b702d37cce086abe59a1a23622ec97c90705a3</originalsourceid><addsrcrecordid>eNpVz81q3DAQAGBTWpqQ5ti7oGdv9S-5h0Ia0iQQyKWF3sxYkm0F23IleZd9qT5j1Wwo5CBGzAzfzFTVR4J3ghD--RB2FBO5k0Ji_KY6J7pRNWe4eVv-nOqaCirPqsuUfIcxUVpIxt5XZ1RT1lClzqs_VykF4yH7sKDQo9EPI5pD5yefj2iIYVvRt8dfNUGwWBSdcWsOEfXlgd3DYpxFw3Q0J8Atdo3BbiYndPB5RGbyizdhhTyGKQzewIR6B3mLLj2PAzdD_l-aYfLDUlTv0hcEKB1T_tfgTRm99-7woXrXw5Tc5Uu8qH5-v_lxfVc_PN7eX1891IZrkuveMq0NWNEIQTmnRkrtGsE4053C1DJljMNaQudEAwQok5Q60yjTYIUFsIvq_uTaAE_tGv0M8dgG8O1zIsShhVjWmlxLGHSUCNqJruMFb4TkmknFBOk5s6RYX0_WunWzs8YtOcL0Cn1dWfzYDmHfCkYxF6wAn16AGH5vLuX2KWxxKfe3REslJOFSsL_9_qYN</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1867561465</pqid></control><display><type>article</type><title>Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>paper, Review</creator><creatorcontrib>paper, Review</creatorcontrib><description>High-mobility group box 1 (HMGB1) is a versatile protein with nuclear and extracellular functions. In the extracellular milieu, HMGB1 binds to several receptors, notably the receptor for advanced glycation end-products (RAGE). The expressions of HMGB1 and RAGE have been described in a variety of cancers. However, the clinical values of HMGB1 and RAGE in haematological malignancies have yet to be evaluated. A systematic search through PubMed and the Web of Science for articles discussing the role of HMGB1 and RAGE in haematological malignancies produced 15 articles. Overexpression of HMGB1 was reported to be associated with malignancy and, in certain studies, poor prognosis and tumour aggressiveness. Only one included study investigated the clinical value of RAGE, in which no significant difference was found between expression of RAGE in CLL neoplastic cells and nonmalignant controls. The discussed associations of HMGB1 and RAGE with clinicopathological characteristics of patients with haematological malignancies warrants further investigation into the prognostic and diagnostic value of both of these molecules.</description><identifier>ISSN: 1428-2526</identifier><identifier>EISSN: 1897-4309</identifier><identifier>DOI: 10.5114/wo.2016.65600</identifier><identifier>PMID: 28239277</identifier><language>eng</language><publisher>Poznan: Termedia Publishing House</publisher><subject>hematological malignancies ; HMGB1 ; leukemia ; lymphoma ; RAGE ; Review Paper</subject><ispartof>Contemporary oncology (Poznań, Poland), 2016-01, Vol.20 (6), p.425-429</ispartof><rights>Copyright Termedia Publishing House 2016</rights><rights>Copyright: © 2017 Termedia Sp. z o. o. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-fd388cad59552442c668e953438b702d37cce086abe59a1a23622ec97c90705a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320453/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1867561465?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,44589,53790,53792</link.rule.ids></links><search><creatorcontrib>paper, Review</creatorcontrib><title>Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review</title><title>Contemporary oncology (Poznań, Poland)</title><description>High-mobility group box 1 (HMGB1) is a versatile protein with nuclear and extracellular functions. In the extracellular milieu, HMGB1 binds to several receptors, notably the receptor for advanced glycation end-products (RAGE). The expressions of HMGB1 and RAGE have been described in a variety of cancers. However, the clinical values of HMGB1 and RAGE in haematological malignancies have yet to be evaluated. A systematic search through PubMed and the Web of Science for articles discussing the role of HMGB1 and RAGE in haematological malignancies produced 15 articles. Overexpression of HMGB1 was reported to be associated with malignancy and, in certain studies, poor prognosis and tumour aggressiveness. Only one included study investigated the clinical value of RAGE, in which no significant difference was found between expression of RAGE in CLL neoplastic cells and nonmalignant controls. The discussed associations of HMGB1 and RAGE with clinicopathological characteristics of patients with haematological malignancies warrants further investigation into the prognostic and diagnostic value of both of these molecules.</description><subject>hematological malignancies</subject><subject>HMGB1</subject><subject>leukemia</subject><subject>lymphoma</subject><subject>RAGE</subject><subject>Review Paper</subject><issn>1428-2526</issn><issn>1897-4309</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpVz81q3DAQAGBTWpqQ5ti7oGdv9S-5h0Ia0iQQyKWF3sxYkm0F23IleZd9qT5j1Wwo5CBGzAzfzFTVR4J3ghD--RB2FBO5k0Ji_KY6J7pRNWe4eVv-nOqaCirPqsuUfIcxUVpIxt5XZ1RT1lClzqs_VykF4yH7sKDQo9EPI5pD5yefj2iIYVvRt8dfNUGwWBSdcWsOEfXlgd3DYpxFw3Q0J8Atdo3BbiYndPB5RGbyizdhhTyGKQzewIR6B3mLLj2PAzdD_l-aYfLDUlTv0hcEKB1T_tfgTRm99-7woXrXw5Tc5Uu8qH5-v_lxfVc_PN7eX1891IZrkuveMq0NWNEIQTmnRkrtGsE4053C1DJljMNaQudEAwQok5Q60yjTYIUFsIvq_uTaAE_tGv0M8dgG8O1zIsShhVjWmlxLGHSUCNqJruMFb4TkmknFBOk5s6RYX0_WunWzs8YtOcL0Cn1dWfzYDmHfCkYxF6wAn16AGH5vLuX2KWxxKfe3REslJOFSsL_9_qYN</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>paper, Review</creator><general>Termedia Publishing House</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BYOGL</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20160101</creationdate><title>Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review</title><author>paper, Review</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-fd388cad59552442c668e953438b702d37cce086abe59a1a23622ec97c90705a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>hematological malignancies</topic><topic>HMGB1</topic><topic>leukemia</topic><topic>lymphoma</topic><topic>RAGE</topic><topic>Review Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>paper, Review</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>East Europe, Central Europe Database</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Contemporary oncology (Poznań, Poland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>paper, Review</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review</atitle><jtitle>Contemporary oncology (Poznań, Poland)</jtitle><date>2016-01-01</date><risdate>2016</risdate><volume>20</volume><issue>6</issue><spage>425</spage><epage>429</epage><pages>425-429</pages><issn>1428-2526</issn><eissn>1897-4309</eissn><abstract>High-mobility group box 1 (HMGB1) is a versatile protein with nuclear and extracellular functions. In the extracellular milieu, HMGB1 binds to several receptors, notably the receptor for advanced glycation end-products (RAGE). The expressions of HMGB1 and RAGE have been described in a variety of cancers. However, the clinical values of HMGB1 and RAGE in haematological malignancies have yet to be evaluated. A systematic search through PubMed and the Web of Science for articles discussing the role of HMGB1 and RAGE in haematological malignancies produced 15 articles. Overexpression of HMGB1 was reported to be associated with malignancy and, in certain studies, poor prognosis and tumour aggressiveness. Only one included study investigated the clinical value of RAGE, in which no significant difference was found between expression of RAGE in CLL neoplastic cells and nonmalignant controls. The discussed associations of HMGB1 and RAGE with clinicopathological characteristics of patients with haematological malignancies warrants further investigation into the prognostic and diagnostic value of both of these molecules.</abstract><cop>Poznan</cop><pub>Termedia Publishing House</pub><pmid>28239277</pmid><doi>10.5114/wo.2016.65600</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1428-2526
ispartof Contemporary oncology (Poznań, Poland), 2016-01, Vol.20 (6), p.425-429
issn 1428-2526
1897-4309
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_13ab2152b5bb470295648367351f43d1
source Publicly Available Content Database; PubMed Central
subjects hematological malignancies
HMGB1
leukemia
lymphoma
RAGE
Review Paper
title Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T19%3A22%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20high%20mobility%20group%20BOX-1%20and%20receptor%20for%20advanced%20glycation%20endproducts%20with%20clinicopathological%20features%20of%20haematological%20malignancies:%20a%20systematic%20review&rft.jtitle=Contemporary%20oncology%20(Poznan%CC%81,%20Poland)&rft.au=paper,%20Review&rft.date=2016-01-01&rft.volume=20&rft.issue=6&rft.spage=425&rft.epage=429&rft.pages=425-429&rft.issn=1428-2526&rft.eissn=1897-4309&rft_id=info:doi/10.5114/wo.2016.65600&rft_dat=%3Cproquest_doaj_%3E4313266441%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c481t-fd388cad59552442c668e953438b702d37cce086abe59a1a23622ec97c90705a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1867561465&rft_id=info:pmid/28239277&rfr_iscdi=true